|
raltegravir |
|
Detailed Prescribing Information |
| Raltegravir = Isentress | |
| Dosing Forms | 400 mg tablets |
| Dosing | 400 mg twice a day |
| Hepatic insufficiency: No adjustment is necessary for mild to moderate hepatic impairment. There is no information regarding severe hepatic insufficiency. | |
| Renal insufficiency: No adjustment needed | |
| Food dependence | May be taken with or without food |
| Adverse Effects | Side effects appear to be very similar to placebo |
| Interactions | Rifampin reduces raltegravir levels and should not be used with raltegravir. |
| Contraindications | Rifampin should not be used with raltegravir due to interaction (see above). |
| Suggested laboratory evaluations | Based on background antiretroviral therapy |
| Warnings | None |
| Full Prescribing Information | http://www.isentress.com |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine | etravirine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Fusion Inhibitors |
| enfuvirtide |
| Co-Receptor Inhibitors |
| maraviroc |
| Integrase inhibitors |
| raltegravir |
Updated 10.17.2007
